EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata

    June 2022 in “ Value in Health ”
    Christian Fenske, Katherine Rosettie, T Lu, C. Ferrufino, M. Borns, Nameirakpam Johnson, Peter Morrow
    Image of study
    TLDR Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
    The study "EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata" conducted a budget impact analysis to estimate the financial implications of adding Baricitinib, an oral Janus kinase inhibitor, to a commercial formulary for treating severe Alopecia Areata (AA). The analysis was based on a hypothetical plan of one million lives, with the number of patients with severe AA eligible for Baricitinib estimated. The study assumed an equi-proportional adoption of Baricitinib, with its uptake increasing from 0.7% to 3.0% over a 5-year period. The net 5-year budget impact was found to be $1,383,345, which is an 11.7% budget increase, or $0.023 per member per month. The study concluded that the addition of Baricitinib to a formulary is expected to have a negligible impact on a commercial plan’s budget.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 11 results

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community I am a dermatologist with a clinical interest in alopecia. AMA

      in Will treatment work for me? 2 years ago
      In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

      community Olumiant active ingredient Baricitinib

      in Research/Science  1 upvotes 2 years ago
      The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

    Related Research

    3 / 3 results